NASDAQ:MOLN

Molecular Partners Q2 2026 Earnings Results & Report

Molecular Partners logo
$2.53 -0.13 (-4.89%)
Closing price 03:58 PM Eastern
Extended Trading
$2.53 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Molecular Partners beat analyst earnings expectations in its Q2 2026 results, released August 24, 2026. The company reported EPS of -$0.44 versus the -$0.45 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
3:00 AM ET

Molecular Partners EPS Results

Actual EPS
-$0.44
Consensus EPS
-$0.45
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Molecular Partners Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Molecular Partners Q2 2026 Earnings FAQ

Molecular Partners (NASDAQ:MOLN) reported earnings of -$0.44 per share for Q2 2026, beating the consensus estimate of -$0.45. The report was announced on Monday, August 24, 2026.

Molecular Partners Earnings Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More Molecular Partners Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Molecular Partners? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Molecular Partners and other key companies, straight to your email.

About Molecular Partners

Molecular Partners (NASDAQ:MOLN) is a Swiss biotechnology company that develops protein-based medicines using its proprietary DARPin platform. Designed ankyrin repeat proteins, or DARPins, are engineered to bind specific biological targets and can be developed to act on one or several targets.

The company’s research focuses on therapeutic candidates for cancer and other serious diseases. Its pipeline has included treatments designed to engage immune cells against tumors and to target proteins found in the tumor environment.

Founded in 2004 as a spin-off from the University of Zurich, Molecular Partners is headquartered in Schlieren, Switzerland. Co-founder Patrick Amstutz has served as its chief executive officer, and the company has pursued research and development through its own programs and collaborations with other biotechnology and pharmaceutical companies.

View Molecular Partners Profile